TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.